Logo
Logo

About Cabazitaxel API

Product
  • Therapeutic CategoryAnti-Cancer/ Oncology

  • CAS Number

    183133-96-2

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, EUDMF, Russia DMF

Mechanism of Action

Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.

Indication

JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Related APIs

Abiraterone Acetate

Anti-Cancer/ Oncology

arrow

Adagrasib

Anti-Cancer/ Oncology

arrow

Apalutamide (Amorphous & Form B)

Anti-Cancer/ Oncology

arrow

Azacitidine

Anti-Cancer/ Oncology

arrow

Bendamustine Hydrochloride

Anti-Cancer/ Oncology

arrow

Bortezomib

Anti-Cancer/ Oncology

arrow

Cabazitaxel

Anti-Cancer/ Oncology

arrow

Cabozantinib HCl

Anti-Cancer/ Oncology

arrow

Cabozantinib S-Malate

Anti-Cancer/ Oncology

arrow

Capecitabine

Anti-Cancer/ Oncology

arrow

Carfilzomib

Anti-Cancer/ Oncology

arrow

Darolutamide

Anti-Cancer/ Oncology

arrow

Dasatinib (Monohydrate)

Anti-Cancer/ Oncology

arrow

Decitabine

Anti-Cancer/ Oncology

arrow

Deucravacitinib

Anti-Cancer/ Oncology

arrow

Enzalutamide

Anti-Cancer/ Oncology

arrow

Eribulin (Available For Selected Markets)

Anti-Cancer/ Oncology

arrow

Fosaprepitant

Anti-Cancer/ Oncology

arrow

Fruquintinib

Anti-Cancer/ Oncology

arrow

Gemcitabine Hydrochloride

Anti-Cancer/ Oncology

arrow

Granisteron

Anti-Cancer/ Oncology

arrow

Lenalidomide (Form A)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate ( MIBK Solvate)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate (Form-C)

Anti-Cancer/ Oncology

arrow

Lomustine

Anti-Cancer/ Oncology

arrow

Midostaurin

Anti-Cancer/ Oncology

arrow

Nilotinib Hydrochloride Monohydrate (Form B)

Anti-Cancer/ Oncology

arrow

Niraparib Tosylate

Anti-Cancer/ Oncology

arrow

Olaparib (Form A)

Anti-Cancer/ Oncology

arrow

Palbociclib

Anti-Cancer/ Oncology

arrow

Pazopanib

Anti-Cancer/ Oncology

arrow

Pemetrexed Disodium Heptahydrate

Anti-Cancer/ Oncology

arrow

Pirtobrutinib

Anti-Cancer/ Oncology

arrow

Pomalidomide

Anti-Cancer/ Oncology

arrow

Relugolix

Anti-Cancer/ Oncology

arrow

Ripretinib

Anti-Cancer/ Oncology

arrow

Ritlecitinib

Anti-Cancer/ Oncology

arrow

Ruxolitinib Phosphate

Anti-Cancer/ Oncology

arrow

Tucatinib

Anti-Cancer/ Oncology

arrow

Venetoclax

Anti-Cancer/ Oncology

arrow

Zanubrutinib

Anti-Cancer/ Oncology

arrow

Zoledronic Acid

Anti-Cancer/ Oncology

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.